These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 18410553)

  • 1. A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study.
    Sathyapalan T; Cho LW; Kilpatrick ES; Coady AM; Atkin SL
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):931-5. PubMed ID: 18410553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS).
    Sathyapalan T; Cho LW; Kilpatrick ES; Coady AM; Atkin SL
    Clin Endocrinol (Oxf); 2009 Jan; 70(1):124-8. PubMed ID: 19128368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.
    Cho LW; Kilpatrick ES; Keevil BG; Coady AM; Atkin SL
    Clin Endocrinol (Oxf); 2009 Feb; 70(2):233-7. PubMed ID: 18547343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance.
    Tan S; Hahn S; Benson S; Dietz T; Lahner H; Moeller LC; Schmidt M; Elsenbruch S; Kimmig R; Mann K; Janssen OE
    Eur J Endocrinol; 2007 Nov; 157(5):669-76. PubMed ID: 17984248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome.
    Sathyapalan T; Javed Z; Kilpatrick ES; Coady AM; Atkin SL
    Clin Endocrinol (Oxf); 2017 Mar; 86(3):384-387. PubMed ID: 27651218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
    Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
    Mitkov M; Pehlivanov B; Terzieva D
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):93-8. PubMed ID: 16360262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study.
    Sathyapalan T; Smith KA; Coady AM; Kilpatrick ES; Atkin SL
    Ann Clin Biochem; 2012 Jan; 49(Pt 1):80-5. PubMed ID: 21972424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
    Hahn S; Quadbeck B; Elsenbruch S; Gärtner R; Finke R; Mann K; Janssen OE
    Dtsch Med Wochenschr; 2004 May; 129(19):1059-64. PubMed ID: 15136950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
    Ortega-González C; Luna S; Hernández L; Crespo G; Aguayo P; Arteaga-Troncoso G; Parra A
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1360-5. PubMed ID: 15598674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
    Singh S; Akhtar N; Ahmad J
    Diabetes Metab Syndr; 2012; 6(4):207-11. PubMed ID: 23199540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.
    Tang T; Glanville J; Hayden CJ; White D; Barth JH; Balen AH
    Hum Reprod; 2006 Jan; 21(1):80-9. PubMed ID: 16199429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome.
    Spranger J; Möhlig M; Wegewitz U; Ristow M; Pfeiffer AF; Schill T; Schlösser HW; Brabant G; Schöfl C
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):738-46. PubMed ID: 15579189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome.
    Esfahanian F; Zamani MM; Heshmat R; Moini nia F
    J Obstet Gynaecol Res; 2013 Apr; 39(4):806-13. PubMed ID: 23279603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study.
    Sathyapalan T; Kilpatrick ES; Coady AM; Atkin SL
    J Clin Endocrinol Metab; 2009 Jan; 94(1):103-8. PubMed ID: 18940877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance.
    Arslanian SA; Lewy V; Danadian K; Saad R
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1555-9. PubMed ID: 11932281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome.
    Nascimento AD; Silva Lara LA; Japur de Sá Rosa-e-Silva AC; Ferriani RA; Reis RM
    Gynecol Endocrinol; 2013 Mar; 29(3):246-9. PubMed ID: 23194004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome.
    Diamanti-Kandarakis E; Kouli C; Tsianateli T; Bergiele A
    Eur J Endocrinol; 1998 Mar; 138(3):269-74. PubMed ID: 9539300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.